GlassScriptPhysician profile
Tamara Ivanova
NPI 1215491634
$2,534.24
in general payments reported to CMS, 2019-2025
20 companies · $556 in 2025
The $556 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $558 · 2022: $425 · 2023: $593 · 2024: $403 · 2025: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,551.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $745.33 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.03 | 2021-2025 | Jardiance |
| Amgen INC. | $222.19 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $212.83 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $205.64 | 2021-2024 | Xarelto |
| Boston Scientific Corporation | $173.76 | 2023-2025 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $149.15 | 2021-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $115.87 | 2021-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $84.14 | 2023-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $60.23 | 2021 | |
| Novo Nordisk INC | $58.25 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $54.63 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $54.13 | 2022-2023 | Verquvo |
| Alnylam Pharmaceuticals INC. | $52.49 | 2025 | Amvuttra |
| Baxter Healthcare | $24.37 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19.19 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $19.15 | 2023 | Arcalyst |
| Glaxosmithkline, LLC. | $18.20 | 2025 | Shingrix |
| Bridgebio Pharma, INC. | $17.45 | 2025 | Attruby |
| Arbor Pharmaceuticals, INC. | $15.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Ivanova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.